G1 Therapeutics Inc.
www.g1therapeutics.com
Latest From G1 Therapeutics Inc.
Tecentriq Takes EU Lead In Triple-Negative Breast Cancer
Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.
Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund
Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.
NCI Director And Former Dx Start-Up Founder Sharpless Will Helm FDA
After a week of speculation as to who will succeed US FDA Commissioner Scott Gottlieb when he steps down next month, Health and Human Services Secretary Alex Azar announced during a congressional hearing that National Cancer Institute Director Ned Sharpless will step in as acting commissioner. One note of medtech interest in Sharpless' bio: he was a co-founder of a diagnostics company.
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- G-Zero Therapeutics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- G1 Therapeutics Inc.
- Senior Management
-
Mark A Velleca, MD, PhD, CEO
Barclay A Phillips, SVP, Corp. Dev. & CFO
Jay C Strum, PhD, CSO
Raj Malik, MD, SVP, R&D & CMO
Mark Avagliano, CBO - Contact Info
-
G1 Therapeutics Inc.
Phone: (919) 213-9835
4501 Research Commons, 79 TW Alexander
Ste. 100
Research Triangle Park, NC 27709
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice